Atinary Technologies’ Post

We are thrilled to be part of the "Enhancing SME Access to European Research and Technology Infrastructures: A Pathway to Innovation & Growth" workshop, which is taking place today in Brussels. The event gathers around the same table representatives from RIs, SMEs, Member States, national funders, and the European Commission to foster collaborations in two strategic domains: advanced materials and biotechnology. At Euro-BioImaging, we believe that European Research Infrastructures (RIs) offer significant yet underused opportunities to support research and innovation for small and medium enterprises. We are contributing with our partners ALBA Synchrotron, ELIXIR, ESRF - The European Synchrotron INESC Brussels HUB to make it easier for SMEs to leverage these advantages. 🔍 We are not just offering services but creating connections within an entire ecosystem to power European innovation and competitiveness in biotechnology and advanced materials. Our goal is to continually improve and facilitate access for SMEs, ensuring they can benefit from available cutting-edge technology and advanced services. Did you know that Euro-BioImaging is a leading imaging initiative in Europe, with a portfolio of over 120 technologies immediately accessible to SMEs? https://lnkd.in/dmCcZpsm 🚀 Our aim is impact. Euro-BioImaging is part of a joint effort by European Research Infrastructures to put their scientific capacity directly at the service of commercial users, accelerating innovation and maintaining Europe's position as a technological global leader. We are particularly eager to engage with the European biotech sector, where our imaging expertise and tech portfolio are unmatched assets. 🌐 We want to break the silos and remove the barriers to research and innovation. During this workshop, participants work jointly towards addressing pressing SMEs needs. The workshop aims to simplify access to RIs' assets, remove administrative hurdles, and create cross-program opportunities. 📈 Euro-BioImaging will implement an SME access pilot as part of our EVOLVE project, taking direct inspiration from the experience of our UK and Belgian Nodes. More about EVOLVE →  https://lnkd.in/dztDRR5n Let's continue to make a difference and drive innovation together! 💪

🌟 Join us at LabDays Stockholm 2024 for an exciting presentation on increasing workflow throughput with acoustics in life sciences! 🌟 Discover how our groundbreaking Echo Acoustic Droplet Ejection (ADE) technology can revolutionize your research applications. Whether you're involved in drug discovery, genomics, proteomics, or functional screening, your research can be accelerated with our Echo Liquid Handlers, which use ultrasonic acoustic energy to precisely dispense nanoliter droplets onto a destination surface. By harnessing the unique power of acoustics, these liquid handlers enable miniaturization of qPCR and NGS assays, drug repurposing through combinatorial screening, and overall increased productivity in such rapidly expanding fields as synthetic biology and high-throughput transcriptomics. You might be surprised by some of the things you hear about our acoustic technology – so we hope you’ll plan to join us! Register here: https://labdays.se/ #LabDaysStockholm2024 #LifeSciences #AcousticTechnology #IncreasedThroughput

🔥 Moore's Law and How It Pertains to Orbitrap Technology🔥 The phrase "Moore's Law" implies something reliable and proven that happens all by itself, like the law of gravity, but Moore's Law is not a law in this sense. In a 1965 article in Electronics Magazine, Gordon E. Moore predicted an annual doubling in the amount of components that would fit on an integrated computer circuit. Because of Moore's Law, new computer models are consistently smaller, lighter, faster and more powerful than earlier models for the same price, with implications for almost every type of business. In the analytical world, i cannot stop myself to pertain the Moore’s law to orbitrap technology. The orbitrap technology breaks the boundaries of analytical chemistry. Refer to below, we found the Moore's law pertains to the past, current and future of the technology of mass spectrometry... https://lnkd.in/gpKDrnb7 https://lnkd.in/gaGPvYwr Mass spectrometry has played a pivotal role in the evolution of analytical chemistry, enabling researchers to identify and quantify molecules with extreme precision and sensitivity. Among the various types of mass spectrometers, OrbitrapTM technology has emerged as one of the most powerful and versatile platforms for chemical analysis. Orbitrap mass spectrometry has established itself as a versatile and powerful platform for chemical analysis, revolutionizing a wide variety of fields. The technology’s high mass resolution, accuracy, and versatility in identifying and quantifying molecules have made it unparalleled in the realm of analytical chemistry. In the ongoing IMSC event in Melbourne Convention and Exhibition Centre from Aug 19, 2024 - Aug 23, 2024 (Booth C), you will get to learn more (if you wish) on scientific changemakers (Mass Spectrometry Technologies) which are helping to shape the future of the global scientific community — from compounds to clinics. https://lnkd.in/dq67ub8e I am a member of the #LBFalumni & #SkyHighTower #GORDONᴛAi #GORDONᴛAiOnMS

The discoveries we make today are the foundation for the innovations of tomorrow. Science shapes the future, one breakthrough at a time. #ScienceToTechnology #InnovateToday #FutureTech #ScientificBreakthroughs #TechEvolution #InnovationJourney #TomorrowStartsToday #worldaileaders

Weekend read 📖 We discuss how EMBL promotes the use of recognition of #preprints, from an institutional perspective, with Victoria Yan, Open Science Research Information Specialist at EMBL. (link in the comments)

What’s holding back Europe’s next scientific revolution? 🔬🚀 Thank you to everyone who joined us at the Palais du Luxembourg for a packed agenda, from early morning sessions through to cocktails and an inspiring visit to the French Senate hemicycle. More than 150 attendees and 30 speakers, brought together by Senator Vanina PAOLI-GAGIN, convened across half a dozen panels to discuss the future of European scientific innovation. Discussions featured insights from leading scientists, investors, startups and major innovation enablers in Europe. Here are some of the key challenges to scientific innovation highlighted: 🔹 Funding Bottleneck - The Valley of Death Many European startups struggle to secure funding after technology validation, but before scaling, creating a stark disadvantage compared to North American peers. 🔹 Regulatory Bottlenecks Environmental Solutions: Environmental solutions that reduce the use of chemical pesticides, such as RNA technology, face a Europe approval timeline of 7 to 9 years, compared to 2 years in the United States. Medical Devices: European companies producing medical devices face an approvals backlog, leading to many to seek initial certification in the United States. Stability & Certainty: Changes in regulation and long term tax uncertainties in Europe were cited as undermining the need for a stable ecosystem that readily enables the transition from research to successful products. 🔹 Potential Path Forward: Regulatory Alignment Among the ideas suggested, was for Europe to consider the UK government’s recent International Recognition Procedure that makes it possible for medicines that have been approved in the EU, USA and other respected jurisdictions, to be approved in the UK in just 60 days. 🔹 Simplifying Funding Complexity of EU funding - so that expensive consultants are needed to even apply - compared to quite simple procedures in some EU states. Let me know if these challenges reflect what you are seeing - or if you understand them differently! Lionel Navarro, Marc-Antoine Authier, exRNA-PATH, COST Association - European Cooperation in Science and Technology, PSL Research University, CNRS, Esther Nolte-'t Hoen, Amy Buck, Hailing Jin, Aude Bernheim, Christophe CLEMENT, Lise ALTER, Carole Caranta, André Le Bivic, Franck Mouthon, Jörg Vogel, Michiel Scheffer, Philippe Boucheron, Dr Isabelle Buckle, Matthieu Coutet, Derek Norman, Laurence de Schoulepnikoff, Jean Schmitt, Neena Mitter, Frédéric Girard, Michel de Lempdes, Antoine Petit, Bruno Rostand, André Loesekrug-Pietri⚡️, Magdalena Skipper

Why Scientists Should Keep Their Big Ideas Alive After attending the Innovation Lab: Quantum for Biotech, hosted by The National Institutes of Health (NIH) and Knowinnovation, Dr. Laia Domingo, PhD shared a powerful reminder for scientists everywhere: “You don’t need to have everything figured out.” As scientists, we can sometimes develop tunnel vision, focusing on challenges we know how to tackle quickly. But imagine the transformative potential of pursuing ideas we don’t yet know how to solve. Laia’s experience at this unique event—designed to spark creative breakthroughs in biomedical research using quantum technologies—reinforced the importance of collaboration and embracing the unknown. Meeting leaders from biotech and quantum technology, she saw firsthand the power of big ideas. Her message to the community: 💡 Keep your big ideas alive. 🤝 Talk to other scientists. 🧠 Brainstorm solutions TOGETHER. Together, we can tackle the mysteries that feel beyond our reach today. Let’s aim higher, think bolder, and collaborate to redefine what’s possible. #Innovation #QuantumBiomedicine #Collaboration #ThinkBig #Community #Collaboration

Alongside operational BRIDGE-building, Evotec is strategically considering challenges and best practices in transitioning from academic drug discovery to an investable proof of concept. Explore these strategic insights in our comprehensive White Paper series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’, where we openly share perspectives to stimulate dialogue among academic researchers, investors, and industry professionals. After presenting the Introduction, Chapter 1, and Chapter 2, today we introduce Chapter 3, titled 'Just Short of a Decathlon: A Day in the Life of a BRIDGE Expert in Residence' which concludes the series. You can download and read all chapters from our Science Pool - https://hubs.ly/Q02J4vnt0 #researchneverstops

Interested in learning how to develop secure and trustworthy confidential data processing and sharing capabilities within the framework of EOSC, IDSA, and FIWARE initiatives, using Health and Farming as real-world examples? Don't miss out on subscribing to the TITAN EOSC newsletter.

Advancing Complement Research: Celebrating Excellence and Looking Ahead 🎉 This year, Dr. Elena Goicoechea de Jorge and Dr. Sophie Chauvet were honored with the prestigious Svar Complement Excellence Award for their groundbreaking contributions to complement research. Their achievements are a powerful reminder of how far the field has come - and the incredible potential that lies ahead. As we reflect on 2024, we celebrate the remarkable progress being made in labs worldwide and look ahead to 2025, a year full of innovation, new discoveries, and breakthroughs that will continue to advance complement science. Don’t miss the inspiring interviews with this year’s award winners! #ComplementResearch #Innovation #SvarLifeScience #ExcellenceInScience #LookingAhead https://hubs.ly/Q0309xnP0